Page 61 - 2020_02-Haematologica-web

Fibrin(ogen): friend and foe
no strong evidence of a causal association between circulating fibrinogen and cardio- vascular disease. Circulation. 2013;128(12): 1310-1324.
58. Ward-Caviness CK, de Vries PS, Wiggins KL, et al. Mendelian randomization evaluation of causal effects of fibrinogen on incident coronary heart disease. PLoS One. 2019;14(5):e0216222.
59. Lovely RS, Falls LA, Al-Mondhiry HA, et al. Association of gammaA/gamma' fibrinogen levels and coronary artery disease. Thromb Haemost. 2002;88(1):26-31.
60. Omarova F, Uitte de Willige S, Simioni P, et al. Fibrinogen γ' increases the sensitivity to activated protein C in normal and factor V Leiden plasma. Blood. 2014;124(9):1531- 1538.
61. Macrae FL, Domingues MM, Casini A, et al. The (patho)physiology of fibrinogen γ'. Semin Thromb Hemost. 2016;42(4):344- 355.
62. Nowak-Gottl U, Weiler H, Hernandez I, et al. Fibrinogen alpha and gamma genes and factor VLeiden in children with thromboem- bolism: results from 2 family-based associa- tion studies. Blood. 2009;114(9):1947-1953.
63. Uitte de Willige S, de Visser MC, Houwing- Duistermaat JJ, et al. Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen gamma' levels. Blood. 2005;106(13):4176-4183.
64. Cheung EY, Uitte de Willige S, Vos HL, et al. Fibrinogen gamma' in ischemic stroke: a case-control study. Stroke. 2008;39(3):1033- 1035.
65. Uitte de Willige S, Doggen CJ, MC DEV, et al. Haplotypes of the fibrinogen gamma gene do not affect the risk of myocardial infarction. J Thromb Haemost. 2006;4(2): 474-476.
66. Soria J, Mirshahi S, Mirshahi SQ, et al. Fibrinogen αC domain: its importance in physiopathology. Res Pract Thromb Haemost. 2019;3(2):173-183.
67. de Maat MP, Verschuur M. Fibrinogen het- erogeneity: inherited and noninherited. Curr Opin Hematol. 2005;12(5):377-383.
68. Carter AM, Catto AJ, Kohler HP, et al. alpha- fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood. 2000;96(3):1177-1179.
69. Morris TA, Marsh JJ, Chiles PG, et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pul- monary hypertension. Blood. 2009;114(9): 1929-1936.
70. Planquette B, Sanchez O, Marsh JJ, et al. Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment. Eur Respir J. 2018;52 (5):1801467.
71. Stec JJ, Silbershatz H, Tofler GH, et al. Association of fibrinogen with cardiovascu- lar risk factors and cardiovascular disease in the Framingham Offspring Population. Circulation. 2000;102(14):1634-1638.
72. Simpson-Haidaris PJ, Rybarczyk B. Tumors and fibrinogen. Ann N Y Acad Sci. 2001;936(1):406-425.
73. Perisanidis C, Psyrri A, Cohen EE, et al. Prognostic role of pretreatment plasma fib- rinogen in patients with solid tumors: a sys- tematic review and meta-analysis. Cancer Treat Rev. 2015;41(10):960-970.
74. Wada H, Mori Y, Okabayashi K, et al. High plasma fibrinogen level is associated with poor clinical outcome in DIC patients. Am J Hematol. 2003;72(1):1-7.
75. Dai K, Zhang Q, Li Y, et al. Plasma fibrino-
gen levels correlate with prognosis and treat- ment outcome in patients with non-M3 acute myeloid leukemia. Leuk Lymphoma. 2019;60(6):1503-1511.
76. Elmoamly S, Afif A. Can biomarkers of coagulation, platelet activation, and inflam- mation predict mortality in patients with hematological malignancies? Hematology. 2018;23(2):89-95.
77. Palumbo JS, Kombrinck KW, Drew AF, et al. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells. Blood. 2000;96(10):3302-3309.
78. Adams GN, Rosenfeldt L, Frederick M, et al. Colon cancer growth and dissemination relies upon thrombin, stromal PAR-1, and fibrinogen. Cancer Res. 2015;75(19):4235- 4243.
79. Sahni A, Simpson-Haidaris PJ, Sahni SK, et al. Fibrinogen synthesized by cancer cells augments the proliferative effect of fibrob- last growth factor-2 (FGF-2). J Thromb Haemost. 2008;6(1):176-183.
80. Roche Y, Pasquier D, Rambeaud JJ, et al. Fibrinogen mediates bladder cancer cell migration in an ICAM-1-dependent path- way. Thromb Haemost. 2003;89(6):1089- 1097.
81. Zheng S, Shen J, Jiao Y, et al. Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity. Cancer Sci. 2009;100(5):859-865.
82. Jennewein C, Tran N, Paulus P, et al. Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med. 2011;17(5-6):568- 573.
83. Sweeney MD, Kisler K, Montagne A, et al. The role of brain vasculature in neurodegen- erative disorders. Nat Neurosci. 2018;21(10):1318-1331.
84. Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol. 2015;7(1): a020412.
85. Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mecha- nisms, imaging and therapeutics. Nat Rev Neurosci. 2018;19(5):283-301.
86. Bowman GL, Kaye JA, Moore M, et al. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance. Neurology. 2007;68(21):1809- 1814.
87. Ujiie M, Dickstein DL, Carlow DA, et al. Blood-brain barrier permeability precedes senile plaque formation in an Alzheimer dis- ease model. Microcirculation. 2003;10(6): 463-470.
88. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169-180.
89. Marik C, Felts PA, Bauer J, et al. Lesion gen- esis in a subset of patients with multiple sclerosis: a role for innate immunity? Brain. 2007;130(Pt 11):2800-2815.
90. Hultman K, Strickland S, Norris EH. The APOE ε4/ε4 genotype potentiates vascular fibrin(ogen) deposition in amyloid-laden vessels in the brains of Alzheimer's disease patients. J Cereb Blood Flow Metab. 2013;33(8):1251-1258.
91. Ryu JK, McLarnon JG. A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer's disease brain. J Cell Mol Med. 2009;13(9a):2911- 2925.
92. Fiala M, Liu QN, Sayre J, et al. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Eur J Clin Invest. 2002;32(5):360-371.
93. Miners JS, Schulz I, Love S. Differing associ-
ations between Aβ accumulation, hypoper- fusion, blood-brain barrier dysfunction and loss of PDGFRB pericyte marker in the pre- cuneus and parietal white matter in Alzheimer's disease. J Cereb Blood Flow Metab. 2018;38(1):103-115.
94. Cortes-Canteli M, Mattei L, Richards AT, et al. Fibrin deposited in the Alzheimer's dis- ease brain promotes neuronal degeneration. Neurobiol Aging. 2015;36(2):608-617.
95. Davalos D, Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012;34(1):43-62.
96. Ryu JK, Petersen MA, Murray SG, et al. Blood coagulation protein fibrinogen pro- motes autoimmunity and demyelination via chemokine release and antigen presentation. Nat Commun. 2015;6:8164.
97. Merlini M, Rafalski VA, Rios Coronado PE, et al. Fibrinogen induces microglia-mediated spine elimination and cognitive impairment in an Alzheimer’s disease model. Neuron. 2019;101(6):1099-1108.
98. Zamolodchikov D, Renne T, Strickland S. The Alzheimer's disease peptide β-amyloid promotes thrombin generation through acti- vation of coagulation factor XII. J Thromb Haemost. 2016;14(5):995-1007.
99. Zamolodchikov D, Strickland S. Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fib- rin. Blood. 2012;119(14):3342-3351.
100.Petersen MA, Ryu JK, Chang KJ, et al. Fibrinogen activates BMP signaling in oligo- dendrocyte progenitor cells and inhibits remyelination after vascular damage. Neuron. 2017;96(5):1003-1012.
101.
Davalos D, Kyu Ryu J, Merlini M, et al. Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nat Commun. 2012;3:1227.
102.Akassoglou K, Yu WM, Akpinar P, et al. Fibrin inhibits peripheral nerve remyelina- tion by regulating Schwann cell differentia- tion. Neuron. 2002;33(6):861-875.
103. Schachtrup C, Lu P, Jones LL, et al. Fibrinogen inhibits neurite outgrowth via beta 3 integrin-mediated phosphorylation of the EGF receptor. Proc Natl Acad Sci U S A. 2007;104(28):11814-11819.
104.Schachtrup C, Ryu JK, Helmrick MJ, et al. Fibrinogen triggers astrocyte scar formation by promoting the availability of active TGF- beta after vascular damage. J Neurosci. 2010;30(17):5843-5854.
105. Montagne A, Nikolakopoulou AM, Zhao Z, et al. Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat Med. 2018;24(3):326- 337.
106. Zou T, Ling C, Xiao Y, et al. Exogenous tis- sue plasminogen activator enhances periph- eral nerve regeneration and functional recov- ery after injury in mice. J Neuropathol Exp Neurol. 2006;65(1):78-86.
107.Ugarova TP, Lishko VK, Podolnikova NP, et al. Sequence γ377−395(P2), but not γ190−202(P1), is the binding site for the αMI-domain of integrin αMβ2 in the γC- domain of fibrinogen. Biochemistry. 2003;42(31):9365-9373.
108. Ryu JK, Rafalski VA, Meyer-Franke A, et al. Fibrin-targeting immunotherapy protects against neuroinflammation and neurodegen- eration. Nat Immunol. 2018;19(11):1212- 1223.
109. van Oijen M, Witteman JC, Hofman A, et al. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke. 2005;36(12):2637-2641.
haematologica | 2020; 105(2)
295